Treatment-resistant depression revisited: a glimmer of hope

A Halaris, E Sohl, EA Whitham - Journal of personalized medicine, 2021 - mdpi.com
Major Depressive Disorder (MDD) is a highly prevalent psychiatric disorder worldwide. It
causes individual suffering, loss of productivity, increased health care costs and high suicide …

Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT

X Wang, C Wang, Y Zhang, Z An - BMC psychiatry, 2023 - Springer
Background Pharmacogenomic testing guided treatment have been developed to guide
drug selection or conversion in major depressive disorder patients. Whether patients benefit …

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient-and rater-blinded, randomized, controlled trial

AK Tiwari, CC Zai, CA Altar, JA Tanner… - Translational …, 2022 - nature.com
The pharmacological treatment of depression consists of stages of trial and error, with less
than 40% of patients achieving remission during first medication trial. However, in a large …

Predicting treatment outcome in depression: an introduction into current concepts and challenges

N Rost, EB Binder, TM Brückl - European Archives of Psychiatry and …, 2023 - Springer
Improving response and remission rates in major depressive disorder (MDD) remains an
important challenge. Matching patients to the treatment they will most likely respond to …

Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis

KG Tesfamicael, L Zhao… - Frontiers in …, 2024 - frontiersin.org
Aim To determine the efficacy and safety of pharmacogenomics (PGx)-guided
antidepressant prescribing in patients with depression through an umbrella review and …

Population Pharmacogenomics in Croatia: Evaluating the PGx Allele Frequency and the Impact of Treatment Efficiency

V Matišić, P Brlek, L Bulić, V Molnar, M Dasović… - International Journal of …, 2023 - mdpi.com
Background: Adverse drug reactions (ADRs) are a significant cause of mortality, and
pharmacogenomics (PGx) offers the potential to optimize therapeutic efficacy while …

Pharmacogenomic clinical support tools for the treatment of depression

ML Baum, AS Widge, LL Carpenter… - American Journal of …, 2024 - psychiatryonline.org
Objective: In this review, the authors update the 2018 report of the American Psychiatric
Association Council of Research Workgroup on Biomarkers and Novel Treatments on …

The role of pharmacogenetics in the treatment of major depressive disorder: a critical review

S Barlati, A Minelli, G Nibbio, L Bertoni… - Frontiers in …, 2023 - frontiersin.org
Pharmacological therapy represents one of the essential approaches to treatment of Major
Depressive Disorder (MDD). However, currently available antidepressant medications show …

Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: a systematic review and meta …

C Santenna, A Shubham, J Ratinder, R Abhijit… - Journal of Affective …, 2024 - Elsevier
Abstract Importance Currently, 30–50% of individuals with depression and 40% with anxiety—
collectively referred to as common mental disorders (CMDs), exhibit inadequate responses …

Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective

JA Tanner, PE Davies, CC Overall, D Grima… - …, 2020 - Taylor & Francis
Aim: Evaluate the cost–effectiveness of combinatorial pharmacogenomic (PGx) testing,
versus treatment as usual (TAU), to guide treatment for patients with depression, from the …